Simon Quick Advisors LLC Buys 1,818 Shares of Zoetis Inc. (NYSE:ZTS)

Simon Quick Advisors LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 60.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,835 shares of the company’s stock after acquiring an additional 1,818 shares during the quarter. Simon Quick Advisors LLC’s holdings in Zoetis were worth $796,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ZTS. Brighton Jones LLC boosted its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Savant Capital LLC boosted its position in shares of Zoetis by 5.3% during the fourth quarter. Savant Capital LLC now owns 6,271 shares of the company’s stock valued at $1,022,000 after buying an additional 313 shares during the period. Stonebridge Financial Group LLC purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $170,000. Portfolio Design Labs LLC boosted its position in shares of Zoetis by 19.4% during the fourth quarter. Portfolio Design Labs LLC now owns 2,799 shares of the company’s stock valued at $456,000 after buying an additional 454 shares during the period. Finally, Avidian Wealth Enterprises LLC boosted its position in shares of Zoetis by 53.5% during the fourth quarter. Avidian Wealth Enterprises LLC now owns 3,564 shares of the company’s stock valued at $581,000 after buying an additional 1,242 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $168.64 on Friday. The business’s fifty day simple moving average is $158.26 and its 200-day simple moving average is $164.09. The company has a market cap of $75.08 billion, a PE ratio of 30.83, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the firm earned $1.38 EPS. The firm’s revenue was up 1.4% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s payout ratio is 35.91%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now directly owns 15,129 shares of the company’s stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Piper Sandler boosted their price target on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.